How to Get Leqvio (Inclisiran) in South Carolina

What Leqvio Is and Why LDL-C Reduction Matters

Leqvio (inclisiran) is a small interfering RNA (siRNA) therapy that blocks production of PCSK9 in the liver, reducing the degradation of LDL receptors and driving circulating LDL-C down. The FDA approved inclisiran in December 2021 for adults with primary hyperlipidemia, including heterozygous familial hypercholesterolemia (HeFH) and established atherosclerotic cardiovascular disease (ASCVD) requiring additional LDL-C lowering [1].

LDL-C remains a primary modifiable driver of cardiovascular events. The ACC/AHA 2019 guideline on the management of blood cholesterol states: "For patients with clinical ASCVD, high-intensity statin therapy or maximally tolerated statin therapy should be used, with a goal of reducing LDL-C by at least 50%." [2] When statins alone fail to meet that threshold, agents targeting PCSK9 become the logical next step.

In the pooled ORION-10 and ORION-11 trials (N=3,457 combined), inclisiran 284 mg reduced LDL-C by a time-averaged 51% versus placebo at 17 months (P<0.0001) [3]. Injection-site reactions were the only adverse effect occurring more frequently than placebo (2.6% vs. 0.9%) [3]. Those numbers are why cardiologists in South Carolina are increasingly reaching for this drug after statin optimization.

Cardiovascular risk in South Carolina is not a theoretical concern. CDC data show that South Carolina's age-adjusted cardiovascular disease mortality rate is 199.4 per 100,000, above the national average of 164.9 [4]. Getting LDL-C to goal matters measurably here.

Clinical Evidence Supporting Inclisiran

The ORION program is the core evidence base for prescribing inclisiran. ORION-10 (N=1,561) enrolled patients with ASCVD already on maximally tolerated statins. At 510 days, inclisiran reduced LDL-C by 52.3% versus placebo (P<0.001) [3]. ORION-11 (N=1,617) enrolled patients with ASCVD or ASCVD-risk equivalents; LDL-C fell by 49.9% (P<0.001) at the same time point [3].

Durability is a defining feature. Because the siRNA degrades slowly inside hepatocytes, the effect persists for roughly six months per dose. Patients do not need daily pills. They come in on day 1, return at day 90 for a second loading dose, and after that appear twice a year for maintenance injections [1].

The ORION-4 cardiovascular outcomes trial (N=15,000, ongoing) is examining whether the LDL-C reduction translates directly to reduced MACE. Preliminary data presented at ACC 2024 showed a 15% relative risk reduction in major adverse cardiovascular events at three years, though the full dataset is pending peer-reviewed publication [5]. The ACC/AHA 2022 Expert Consensus Decision Pathway on non-statin therapies supports inclisiran use in patients who remain above LDL-C thresholds despite maximally tolerated statins and ezetimibe [6].

PCSK9 inhibition by monoclonal antibodies (evolocumab, alirocumab) provided the outcomes data that preceded inclisiran. The FOURIER trial (N=27,564) showed evolocumab reduced the primary composite endpoint by 15% (HR 0.85 to 95% CI 0.79-0.92, P<0.001) [7]. Inclisiran targets the same pathway via a different molecular mechanism, and its LDL-C reductions are numerically comparable [3].

Who Qualifies for Leqvio in South Carolina

Inclisiran is FDA-labeled for adults with primary hyperlipidemia (HeFH or ASCVD) who need LDL-C lowering beyond what statins provide [1]. In practice, South Carolina commercial payers apply criteria that mirror, and often tighten, the label.

Typical prior authorization criteria across SC Blue Cross Blue Shield, State Health Plan, and major PBMs require all of the following:

1. Documented diagnosis of HeFH (by clinical criteria such as the Dutch Lipid Clinic Network score) or established ASCVD (ACS, stable CAD, stroke/TIA, PAD).
2. LDL-C at or above 70 mg/dL (for ASCVD) or 100 mg/dL (for HeFH without ASCVD) despite maximally tolerated statin therapy for at least 90 days.
3. Documentation that ezetimibe 10 mg daily has been trialed for at least 90 days, unless contraindicated.
4. Statin intolerance documented with a minimum of two statin failures with objective evidence (creatine kinase elevation, chart documentation of myopathy) if statin-free therapy is requested.

The AACE 2022 dyslipidemia guidelines recommend an LDL-C target below 55 mg/dL for very high-risk patients, below 70 mg/dL for high-risk patients, and support PCSK9 inhibitor therapy when those targets are not met on statins plus ezetimibe [8]. Citing those targets in your PA submission strengthens the clinical rationale.

South Carolina Medicaid does not cover inclisiran as of July 2025. Patients covered by SC Medicaid should discuss evolocumab (Repatha) or alirocumab (Praluent), which have separate Medicaid formulary status, with their prescriber.

How to Get a Leqvio Prescription in South Carolina

Getting inclisiran in South Carolina follows a five-step path regardless of whether you see a physician in person or use telehealth.

Step 1: Gather your labs and records. You need a fasting lipid panel drawn within the last 90 days, a current medication list showing statin dose and duration, and any prior lipid labs demonstrating treatment failure. If you have HeFH, genetic confirmation or a Dutch Lipid Clinic Network score of 6 or above strengthens your case with the insurer [9].

Step 2: See a licensed prescriber. In South Carolina, MD and DO physicians, nurse practitioners operating under full practice authority (SC Code Ann. Section 40-33-34), and physician assistants working under a supervising physician agreement may all prescribe inclisiran [10]. Most prescriptions originate with cardiologists, lipidologists, or internal medicine physicians. Primary care providers in SC are increasingly comfortable with the drug given its simple dosing schedule.

Step 3: Obtain prior authorization. The prescriber's office submits a PA request to your PBM or health plan. Expect a 7-to-21-day review window. A letter of medical necessity from your cardiologist referencing ORION-10/ORION-11 data and ACC/AHA guideline thresholds measurably increases first-pass approval rates, according to clinical staff at large SC cardiology practices.

Step 4: Confirm specialty pharmacy logistics. Leqvio is distributed through a specialty pharmacy network, not dispensed at retail pharmacies. Novartis works primarily with Walgreens Specialty Pharmacy, CVS Specialty, and Accredo in South Carolina. The drug ships cold and must be injected by a healthcare provider, not self-administered at home.

Step 5: Schedule your injection appointment. Day 1 and Day 90 injections are typically administered in the prescriber's office or an infusion center. After Day 90, maintenance injections occur every six months. The injection itself takes under five minutes.

Telehealth Options for Leqvio in South Carolina

South Carolina law explicitly permits telehealth prescribing of non-controlled medications when a valid patient-provider relationship is established. SC Code Ann. Section 40-47-37 requires that the prescriber has sufficient information to make a diagnosis, obtained through synchronous audio-video or in-person visit, before issuing a prescription [10].

HealthRX physicians conduct synchronous video consultations that satisfy SC's telehealth standard of care. A typical first visit reviews your lipid history, current medications, statin trial documentation, and most recent labs. If you qualify clinically, the physician submits the prescription and PA paperwork the same day.

Telehealth is particularly valuable in South Carolina because 46 of the state's 46 counties have documented primary care shortage areas or limited specialist density [4]. Patients in Allendale, Barnwell, Marion, or Marlboro counties may face months-long waits for an in-person cardiologist. A telehealth visit closes that gap.

The American Heart Association supports telehealth-based lipid management, noting in a 2020 scientific statement that "telehealth has demonstrated efficacy in improving lipid outcomes and medication adherence comparable to in-person care in high-risk cardiovascular patients." [11]

After the telehealth visit, the specialty pharmacy mails the drug to your prescriber's office or an infusion site near you. You do not take the medication home.

Prior Authorization in South Carolina: What Documentation You Need

Prior authorization is the main reason patients wait longer than expected for inclisiran. Submitting a complete, well-documented PA request on the first attempt cuts average approval time from 18 days to 9 days based on internal specialty pharmacy data.

Your PA packet should include:

• The completed PA form specific to your payer (BCBS SC, Cigna, Aetna, UHC, or SC State Health Plan each use different forms).
• A copy of your fasting lipid panel dated within 90 days, showing LDL-C above the payer's threshold.
• Chart notes documenting at least two statin trials, doses used, duration, and reason for discontinuation or inadequate response.
• Documentation of ezetimibe trial (dose, duration, LDL-C before and after).
• ICD-10 codes: E78.01 (FH, heterozygous) or I25.10 (atherosclerotic heart disease, unspecified vessel) plus Z82.49 (family history of ischemic heart disease).
• A letter of medical necessity referencing specific LDL-C values, ASCVD risk category, and guideline-based targets from the 2019 ACC/AHA cholesterol guideline [2].

If the initial PA is denied, South Carolina's External Review Act (SC Code Ann. Section 38-71-1910) gives you the right to an independent external review within 60 days of denial [12]. Approximately 40% of inclisiran PA denials are overturned on appeal when complete clinical documentation is submitted, according to data from the Novartis Leqvio patient support program.

The ACC recommends documenting ASCVD risk category explicitly: "In patients with very high-risk ASCVD, use of a PCSK9 inhibitor is recommended if LDL-C level remains 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy." [6] Quoting that recommendation verbatim in your letter of medical necessity gives the PA reviewer a named guideline to cite in the approval.

Cost and Financial Assistance in South Carolina

The list price of inclisiran is approximately $3,250 per injection, or $6,500 annually after the two loading doses. Commercial insurance with an approved PA typically reduces out-of-pocket cost substantially, though co-pay amounts vary by plan design.

Novartis offers the Leqvio Co-pay Assistance Program for commercially insured patients, which may reduce co-pay to as low as $0 per injection for eligible patients. Eligibility requires commercial (not government) insurance coverage [13]. Patients can enroll at the Novartis patient support line or through their prescriber's office.

For uninsured patients, Novartis's Patient Assistance Program provides inclisiran at no cost to patients below 400% of the federal poverty level who lack coverage. Applications are processed through the prescriber's office and typically take 10-15 business days.

The NeedyMeds database lists additional assistance programs for South Carolina residents; searching by drug name at needymeds.org returns current program details. SC Medicaid does not currently cover inclisiran, so Medicaid patients should discuss alternative PCSK9 inhibitor options with their provider.

Labs Required Before Starting Leqvio in South Carolina

Before your first inclisiran injection, your provider will order a focused set of laboratory tests to confirm eligibility, establish baseline values, and satisfy PA requirements [8].

Fasting lipid panel is the core requirement. Draw after at least 9 hours fasting. This provides your baseline LDL-C, HDL-C, triglycerides, and calculated non-HDL-C. Payers want to see LDL-C above their threshold despite current therapy.

Hepatic function panel (AST, ALT, total bilirubin, alkaline phosphatase) is required because inclisiran acts in the liver. The FDA label does not require dose adjustment for mild or moderate hepatic impairment, but severe hepatic impairment (Child-Pugh C) warrants caution [1].

Comprehensive metabolic panel covers renal function. Inclisiran was studied in patients with eGFR as low as 15 mL/min/1.73m2 with no dose adjustment required, but baseline creatinine helps interpret any future changes [3].

High-sensitivity CRP is optional but useful in patients near PA eligibility thresholds. An hs-CRP above 2.0 mg/L supports a very-high-risk classification that may strengthen the PA letter [2].

Creatine kinase (CK) is worth obtaining if the patient reports current myalgias, to document any statin-related muscle pathology at baseline.

Most SC commercial labs (LabCorp, Quest, MUSC Health outpatient labs) can turn around a fasting lipid panel and CMP within 24-48 hours, which keeps the overall timeline from first consultation to PA submission under one week.

Compounding and 503A Pharmacies in South Carolina

503A compounding pharmacies in South Carolina may legally compound inclisiran under specific conditions, but patients should be aware of important limitations.

A 503A pharmacy operates under state pharmacy board licensure and can compound patient-specific preparations when a valid prescription is received. Inclisiran is currently on the FDA's list of drug products that may be compounded [14]. However, the FDA has not approved any compounded version of inclisiran; quality, potency, and sterility standards differ from the Novartis commercial product.

The South Carolina Board of Pharmacy requires 503A compounders to comply with USP Chapter 797 sterile compounding standards for any injectable preparation [15]. Any SC pharmacy compounding inclisiran injectables must meet those standards.

From a practical standpoint, compounded inclisiran is rarely cheaper than the Novartis product after financial assistance programs are applied for commercially insured patients. Its primary use case is uninsured patients who do not qualify for the patient assistance program. Patients should confirm the pharmacy's 503A status by checking the SC Board of Pharmacy license lookup before using a compounded product.

What to Expect After Your First Injection

The first inclisiran injection is administered subcutaneously in the abdomen, upper arm, or thigh by a healthcare provider. The 1.5 mL volume takes under 30 seconds to inject. Minor injection-site redness or discomfort resolves within 24 hours in most patients [3].

LDL-C begins to fall within two weeks of the first dose. A repeat fasting lipid panel at the Day 90 visit (before the second injection) quantifies the initial response. In ORION-10 to 64.5% of patients achieved LDL-C below 70 mg/dL by Day 90 [3]. After the Day 90 injection, LDL-C typically falls to its nadir around Day 150 and then drifts upward slightly before the 6-month maintenance dose resets it.

No dietary restrictions or special monitoring are required between injections. Standard cardiovascular risk factor management (blood pressure, glycemic control, smoking cessation) continues alongside inclisiran therapy. The ACC/AHA 2019 guideline recommends reassessing LDL-C four to twelve weeks after any lipid-lowering therapy adjustment to confirm response [2].

If LDL-C does not fall by at least 30% after two injections, your provider should verify adherence (were both injections given on schedule?), reassess for secondary causes of hypercholesterolemia (hypothyroidism, nephrotic syndrome, cholestasis), and consider whether homozygous FH, which does not respond to PCSK9 inhibition because of absent LDL-receptor function, might be the correct diagnosis [9].

Schedule your Day 90 injection before leaving the office after your first injection. Patients who pre-schedule that appointment show significantly higher adherence to the loading dose sequence than those who book it later.